Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Forecast
Data as of May 3, 2026Healthcare · Current price $2.05 (+10.81%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Nov 14, 2024 | Etzer Darout | BMO Capital | $27.00 | +1217.1% |
| Sep 16, 2024 | Etzer Darout | BMO Capital | $28.00 | +1265.9% |
| Aug 13, 2024 | Matthew Biegler | Oppenheimer | $18.00 | +778.0% |
| May 14, 2024 | Matthew Biegler | Oppenheimer | $21.00 | +924.4% |
| May 14, 2024 | Emily Bodnar | H.C. Wainwright | $22.00 | +973.2% |
| May 14, 2024 | Etzer Darout | BMO Capital | $25.00 | +1119.5% |
| Apr 25, 2024 | Joseph Catanzaro | Piper Sandler | $30.00 | +1363.4% |
| Apr 25, 2024 | Silvan Tuerkcan | JMP Securities | $17.00 | +729.3% |
| Mar 28, 2024 | Emily Bodnar | H.C. Wainwright | $20.00 | +875.6% |
| Dec 11, 2022 | Joseph Catanzaro | Piper Sandler | $25.00 | +1119.5% |
Top Analysts Covering ACRV
ACRV vs Sector & Market
| Metric | ACRV | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 2 | 8 | 18 |
| Target Upside | +964.9% | +1149.1% | +14.9% |
| P/E Ratio | -0.94 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2M | $2M | $2M | 5 |
| 2027-12-31 | $4M | $4M | $4M | 5 |
| 2028-12-31 | $21M | $21M | $21M | 5 |
| 2029-12-31 | $71M | $71M | $71M | 2 |
| 2030-12-31 | $144M | $144M | $144M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-2.59 | $-2.18 | $-1.85 | 6 |
| 2027-12-31 | $-2.46 | $-1.95 | $-1.24 | 5 |
| 2028-12-31 | $-4.25 | $-2.12 | $-0.71 | 5 |
| 2029-12-31 | $-1.75 | $-1.75 | $-1.75 | 1 |
| 2030-12-31 | $-0.97 | $-0.97 | $-0.97 | 1 |
Frequently Asked Questions
What is the analyst consensus for ACRV?
The consensus among 2 analysts covering Acrivon Therapeutics, Inc. Common Stock (ACRV) is Buy with an average price target of $21.83.
What is the highest price target for ACRV?
The highest price target for ACRV is $30.00, set by Joseph Catanzaro at Piper Sandler on 2024-04-25.
What is the lowest price target for ACRV?
The lowest price target for ACRV is $17.00, set by Silvan Tuerkcan at JMP Securities on 2024-04-25.
How many analysts cover ACRV?
2 analysts have issued ratings for Acrivon Therapeutics, Inc. Common Stock in the past 12 months.
Is ACRV a buy or sell right now?
Based on 2 analyst ratings, ACRV has a consensus rating of Buy (2.00/5) with a +964.9% upside to the consensus target of $21.83.
What are the earnings estimates for ACRV?
Analysts estimate ACRV will report EPS of $-2.18 for the period ending 2026-12-31, with revenue estimated at $2M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.